Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Thomas Reiner
Sloan Kettering Inst Can Research, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Summit Biomedical Imaging, LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The central hypothesis of the proposal is PARP1 targeted fluorescence imaging may improve existing screening practices for both EAC and its precursor lesions. The goal is to show that a topical application technology using an innovative applicator will enable localized, specific contrast generation at the target site without the need for systemic administration. Dr. Reiner is a co-founder of Summit Biomedical Imaging, which is a company focused on discovery and development of diagnostic imaging agents targeting PARP1. There is a business overlap with Summit Biomedical Imaging because the company may have an interest in the research results.
Evaluation of PARP1 targeted imaging as screening tool for esophageal adenocarcinoma
Project Narrative This proposal is dedicated to the development of a targeted fluorescence-guided imaging approach for early detection of esophageal cancer, which could integrate into currently practiced white light surveillance endoscopy in Barrett's esophagus patients. Improved early detection is imperative to increase prognosis and the 5-Year survival rate that remains under 20%, however validated molecular imaging techniques are currently unavailable for this patient population. We aim to show that our innovative imaging approach consisting of topical application of a contrast agent targeted against the nuclear DNA repair enzyme, PARP1, has sensitivity and specificity that is superior to the current standard-of-care detection methods.
Filed on December 14, 2018.
Tell us what you know about Thomas Reiner's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Thomas Reiner”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Thomas Reiner | Sloan Kettering Inst Can Research | Conflict of Interest | Theragnostics, Ltd | $10,000 - $19,999 |
| Thomas Reiner | Sloan Kettering Inst Can Research | Conflict of Interest | Summit Biomedical Imaging, LLC | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.